Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025)

Mereo BioPharma (MREO) posted quarterly EBITDA Margin of 2099.8% for Q2 2025, down 194.58% quarter-over-quarter from 712.8% in Q4 2023.

Mereo BioPharma (MREO) EBITDA Margin (2023 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported EBITDA Margin for 2 consecutive years, with 2099.8% the latest figure, recorded in Q2 2025.

In Q2 2025, EBITDA Margin changed N/A year-over-year to 2099.8%; the TTM figure through Dec 2025 stood at 8021.2% (changed N/A YoY), while the FY2025 annual figure was 8021.4%, changed N/A from the prior year.
EBITDA Margin slipped to 2099.8% in Q2 2025 per MREO's latest filing, from 712.8% in the prior quarter.
Across five years, EBITDA Margin topped out at 9.01% in Q2 2023 and bottomed at 2099.8% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn	30.15%
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn	32.54%
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn	-35.57%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.30 Bn	26.46 Bn	-	19.75%
10	Mereo BioPharma	47.41 Mn	47.41 Mn	-	-

Download Data